OTLK
NASDAQOutlook Therapeutics Inc.
Website
News25/Ratings12
News · 26 weeks41-27%
2025-10-262026-04-19
Mix2990d
- SEC Filings16(55%)
- Other8(28%)
- Offering5(17%)
Latest news
25 items- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics" or the "Company"), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 16,129,033 shares of its common stock at an offering price of $0.31 per share of common stock. Additionally, in a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 16,129,033 shares of common stock at an exercise price
- SECSEC Form 424B5 filed by Outlook Therapeutics Inc.424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics" or the "Company"), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company will issue unregis
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed its Federal Dispute Resolution meeting with the Office of New Drugs at the U.S. Food and Drug Administration (FDA). The meeting was conducted as part of the Company's ongoing efforts to seek alignment with the FDA regarding the regulatory pathway for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) and as a follow-up to its recent Type A meeting with the Division of Ophthalmology and Office of Specialty Medicine regarding the December 30, 2025 Compl
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDAISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has granted a meeting with the deciding official to be conducted
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces Closing of $5.0 Million Public OfferingISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Each common warrant has an exercise price of $0.25 per share, is exercisable immediately and expires five years from the date of issuance. The aggrega
- PROutlook Therapeutics Announces Pricing of $5.0 Million Public OfferingISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant are being sold together at a combined public offering price of $0.25. The aggregate gross proceeds of the offering are expected to be $5.0 million, before deducting placement agent fees and other offering expenses. E
- PROutlook Therapeutics Announces Proposed Public OfferingISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts public offering of its common stock (or pre-funded warrants in lieu thereof) and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Outlook T
- SECSEC Form 424B5 filed by Outlook Therapeutics Inc.424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible NoteISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC (the "Existing Note") and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC (the "New Note"). Under the amendment to the Existing Note, the maturity date of the Existing Note has been extended to December 31, 2026, with no other changes to the terms. The lender has confirmed that the Existing Note is not in default. In addition, Outlook Therapeutics entered int
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg). The Type A meeting was conducted to clarify the outstanding issue identified in the CRL regarding substantial evidence of effectiveness and to discuss potential paths forward for regulatory approval. "We appreciate the F
- PROutlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in SwitzerlandVeteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership advances European commercial expansion strategy, with LYTENAVA™ (bevacizumab gamma) expected to launch in Switzerland in 2027 ISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases and Mediconsult AG, Switzerland's leading full-service partner for ophthalmic professionals, today announced th
- SECSEC Form 8-K filed by Outlook Therapeutics Inc.8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form 10-Q filed by Outlook Therapeutics Inc.10-Q - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdateContinued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request submitted to the U.S. Food and Drug Administration for ONS-5010 ISELIN, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for the first quarter fiscal year 2026 and provided a corporate update. "LYTENAVA™ (bevacizumab gamma) is demonstrating increasing adoption in Europe following our initial launches, with gr
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)